Shanghai Cell Therapy Closes $40 Million C1 Round for Cancer Drugs

Shanghai Cell Therapy completed a $40 million Series C1 financing, led by China Industrial Asset Management, which contributed $26 million of the total. Shanghai Cell Therapy is developing oncology drugs based on precision medicine and cell therapy technologies. The company has established the Shanghai Wu Mengchao-Nobel Laureate Joint Medical Technology and Innovation Center. It claims the center has developed over 45 immune cell technologies and been awarded 16 China and two American patents. More details....

Share this with colleagues:

Original Article: Shanghai Cell Therapy Closes $40 Million C1 Round for Cancer Drugs

More From BioPortfolio on "Shanghai Cell Therapy Closes $40 Million C1 Round for Cancer Drugs"